Skip to main content
SpringerLink
Log in

Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Myopic choroidal neovascularization (mCNV) is the second most common form of CNV after age-related macular degeneration (AMD). It is a sight-threatening complication of pathologic myopia (PM) and often affects patients in their working years causing significant impact on quality of life. Previous therapies such as photodynamic therapy with verteporfin have shown limited success. Due to the similarities in pathogenesis of mCNV and AMD CNV, anti-vascular endothelial growth factor therapy (anti-VEGF), which has so far been the mainstay of treatment for AMD CNV, has been shown to be effective in the treatment of mCNV and has become the first-line treatment of choice. This article aims to examine briefly the epidemiology and pathophysiology of mCNV, as well as review the evidence for efficacy, safety, and clinical use of anti-VEGF treatment for mCNV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet. 2012;379(9827):1739–48. doi:10.1016/S0140-6736(12)60272-4.

    Article  PubMed  Google Scholar 

  2. Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157(1):9–25 e12. doi:10.1016/j.ajo.2013.08.010.

  3. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial–VIP report no. 3. Ophthalmology. 2003;110(4):667–73.

    Article  PubMed  Google Scholar 

  4. Lai TY. Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: do we need more evidence? Retina. 2012;32(8):1443–5. doi:10.1097/IAE.0b013e31826956e4.

    Article  PubMed  Google Scholar 

  5. Baldwin WR. A review of statistical studies of relations between myopia and ethnic, behavioral, and physiological characteristics. Am J Optom Physiol Opt. 1981;58(7):516–27.

    Article  CAS  PubMed  Google Scholar 

  6. Wolfram C, Hohn R, Kottler U, Wild P, Blettner M, Buhren J, et al. Prevalence of refractive errors in the European adult population: the Gutenberg Health Study (GHS). Br J Ophthalmol. 2014;98(7):857–61. doi:10.1136/bjophthalmol-2013-304228.

    Article  PubMed  Google Scholar 

  7. Pan CW, Cheng CY, Saw SM, Wang JJ, Wong TY. Myopia and age-related cataract: a systematic review and meta-analysis. Am J Ophthalmol. 2013;156(5):1021–33 e1. doi:10.1016/j.ajo.2013.06.005.

  8. Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ. 2008;86(1):63–70.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Liu HH, Xu L, Wang YX, Wang S, You QS, Jonas JB. Prevalence and progression of myopic retinopathy in Chinese adults: the Beijing Eye Study. Ophthalmology. 2010;117(9):1763–8. doi:10.1016/j.ophtha.2010.01.020.

    Article  PubMed  Google Scholar 

  10. Ohno-Matsui K, Kawasaki R, Jonas JB, Cheung CM, Saw SM, Verhoeven VJ, et al. International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol. 2015;159(5):877–83. doi:10.1016/j.ajo.2015.01.022.

    Article  PubMed  Google Scholar 

  11. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology. 1984;91(12):1573–81.

    Article  CAS  PubMed  Google Scholar 

  12. Hsu WM, Cheng CY, Liu JH, Tsai SY, Chou P. Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2004;111(1):62–9. doi:10.1016/j.ophtha.2003.05.011.

    Article  PubMed  Google Scholar 

  13. Iwase A, Araie M, Tomidokoro A, Yamamoto T, Shimizu H, Kitazawa Y, et al. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study. Ophthalmology. 2006;113(8):1354–62. doi:10.1016/j.ophtha.2006.04.022.

    Article  PubMed  Google Scholar 

  14. Curtin BJ, Karlin DB. Axial length measurements and fundus changes of the myopic eye. Am J Ophthalmol. 1971;71(1 Pt 1):42–53.

    Article  CAS  PubMed  Google Scholar 

  15. Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Kojima A, Hayashi W, et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology. 2010;117(8):1595–611, 611 e1–4. doi:10.1016/j.ophtha.2009.11.003.

  16. Neelam K, Cheung CM, Ohno-Matsui K, Lai TY, Wong TY. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012;31(5):495–525. doi:10.1016/j.preteyeres.2012.04.001.

    Article  CAS  PubMed  Google Scholar 

  17. Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol. 2003;87(5):570–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol. 1981;91(2):177–83.

    Article  CAS  PubMed  Google Scholar 

  19. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141(3):456–62. doi:10.1016/j.ajo.2005.10.012.

    Article  CAS  PubMed  Google Scholar 

  20. Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997;151(1):281–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Moriyama M, Ohno-Matsui K, Futagami S, Yoshida T, Hayashi K, Shimada N, et al. Morphology and long-term changes of choroidal vascular structure in highly myopic eyes with and without posterior staphyloma. Ophthalmology. 2007;114(9):1755–62. doi:10.1016/j.ophtha.2006.11.034.

    Article  PubMed  Google Scholar 

  22. Xu L, Li Y, Wang S, Wang Y, Wang Y, Jonas JB. Characteristics of highly myopic eyes: the Beijing Eye Study. Ophthalmology. 2007;114(1):121–6. doi:10.1016/j.ophtha.2006.05.071.

    Article  PubMed  Google Scholar 

  23. You QS, Peng XY, Xu L, Chen CX, Wang YX, Jonas JB. Myopic maculopathy imaged by optical coherence tomography: the beijing eye study. Ophthalmology. 2014;121(1):220–4. doi:10.1016/j.ophtha.2013.06.013.

    Article  PubMed  Google Scholar 

  24. Curtin BJ. Physiologic vs pathologic myopia: genetics vs environment. Ophthalmology. 1979;86(5):681–91.

    Article  CAS  PubMed  Google Scholar 

  25. Seko Y, Seko Y, Fujikura H, Pang J, Tokoro T, Shimokawa H. Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest Ophthalmol Vis Sci. 1999;40(13):3287–91.

    CAS  PubMed  Google Scholar 

  26. Wakabayashi T, Ikuno Y. Choroidal filling delay in choroidal neovascularisation due to pathological myopia. Br J Ophthalmol. 2010;94(5):611–5. doi:10.1136/bjo.2009.163535.

    Article  PubMed  Google Scholar 

  27. Young TL. Dissecting the genetics of human high myopia: a molecular biologic approach. Trans Am Ophthalmol Soc. 2004;102:423–45.

    PubMed  PubMed Central  Google Scholar 

  28. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology. 1983;90(8):923–6.

    Article  CAS  PubMed  Google Scholar 

  29. Secretan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol. 1997;7(4):307–16.

    CAS  PubMed  Google Scholar 

  30. Teo K, Gemmy Cheung C. Choroidal neovascularization secondary to pathological myopia. World J Ophthalmol. 2014;4(3):35–46.

  31. Ikuno Y, Sayanagi K, Soga K, Sawa M, Gomi F, Tsujikawa M, et al. Lacquer crack formation and choroidal neovascularization in pathologic myopia. Retina. 2008;28(8):1124–31. doi:10.1097/IAE.0b013e318174417a.

    Article  PubMed  Google Scholar 

  32. Cheung CM, Loh BK, Li X, Mathur R, Wong E, Lee SY, et al. Choroidal thickness and risk characteristics of eyes with myopic choroidal neovascularization. Acta Ophthalmol. 2013;91(7):e580–1. doi:10.1111/aos.12117.

    Article  PubMed  Google Scholar 

  33. Kim YM, Yoon JU, Koh HJ. The analysis of lacquer crack in the assessment of myopic choroidal neovascularization. Eye. 2011;25(7):937–46. doi:10.1038/eye.2011.94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bruyere E, Caillaux V, Cohen SY, Martiano D, Ores R, Puche N, et al. Spectral-domain optical coherence tomography of subretinal hyperreflective exudation in myopic choroidal neovascularization. Am J Ophthalmol. 2015;160(4):749–58. doi:10.1016/j.ajo.2015.07.004.

    Article  PubMed  Google Scholar 

  35. Milani P, Pece A, Pierro L, Bergamini F. Imaging of naive myopic choroidal neovascularization by spectral-domain optical coherence tomography. Ophthalmol J Int d’ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkunde. 2014;232(1):28–36. doi:10.1159/000357980.

    Article  Google Scholar 

  36. Baba T, Ohno-Matsui K, Yoshida T, Yasuzumi K, Futagami S, Tokoro T, et al. Optical coherence tomography of choroidal neovascularization in high myopia. Acta Ophthalmol Scand. 2002;80(1):82–7.

    Article  PubMed  Google Scholar 

  37. Hee MR, Baumal CR, Puliafito CA, Duker JS, Reichel E, Wilkins JR, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology. 1996;103(8):1260–70.

    Article  CAS  PubMed  Google Scholar 

  38. Ohno-Matsui K, Ito M, Tokoro T. Subretinal bleeding without choroidal neovascularization in pathologic myopia. A sign of new lacquer crack formation. Retina. 1996;16(3):196–202.

    Article  CAS  PubMed  Google Scholar 

  39. Leung TG, Moradi A, Liu D, Nguyen QD, Dunn JP, Burkholder B, et al. Clinical features and incidence rate of ocular complications in punctate inner choroidopathy. Retina. 2014;34(8):1666–74. doi:10.1097/IAE.0000000000000125.

    Article  PubMed  Google Scholar 

  40. Watzke RC, Packer AJ, Folk JC, Benson WE, Burgess D, Ober RR. Punctate inner choroidopathy. Am J Ophthalmol. 1984;98(5):572–84.

    Article  CAS  PubMed  Google Scholar 

  41. Vance SK, Khan S, Klancnik JM, Freund KB. Characteristic spectral-domain optical coherence tomography findings of multifocal choroiditis. Retina. 2011;31(4):717–23. doi:10.1097/IAE.0b013e318203c1ef.

    Article  PubMed  Google Scholar 

  42. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103(8):1241–4.

    Article  CAS  PubMed  Google Scholar 

  43. Mauget-Faysse M, Cornut PL, Quaranta El-Maftouhi M, Leys A. Polypoidal choroidal vasculopathy in tilted disk syndrome and high myopia with staphyloma. Am J Ophthalmol. 2006;142(6):970–5. doi:10.1016/j.ajo.2006.06.063.

    Article  PubMed  Google Scholar 

  44. Kang HM, Koh HJ. Lack of polypoidal lesions in patients with myopic choroidal neovascularization as evaluated by indocyanine green angiography. Am J Ophthalmol. 2014;157(2):378–83 e1. doi:10.1016/j.ajo.2013.09.018.

  45. Caillaux V, Gaucher D, Gualino V, Massin P, Tadayoni R, Gaudric A. Morphologic characterization of dome-shaped macula in myopic eyes with serous macular detachment. Am J Ophthalmol. 2013;156(5):958–67 e1. doi:10.1016/j.ajo.2013.06.032.

  46. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003;110(7):1297–305. doi:10.1016/s0161-6420(03)00461-5.

    Article  PubMed  Google Scholar 

  47. Kojima A, Ohno-Matsui K, Teramukai S, Ishihara Y, Shimada N, Yoshida T, et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2006;244(11):1474–9. doi:10.1007/s00417-006-0324-4.

  48. Ohno-Matsui K, Yoshida T. Myopic choroidal neovascularization: natural course and treatment. Curr Opin Ophthalmol. 2004;15(3):197–202.

    Article  PubMed  Google Scholar 

  49. Chan WM, Ohji M, Lai TY, Liu DT, Tano Y, Lam DS. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol. 2005;89(11):1522–8. doi:10.1136/bjo.2005.074716.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994;101(12):1953–61.

    Article  CAS  PubMed  Google Scholar 

  51. Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Luke M, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006;142(1):95–104. doi:10.1016/j.ajo.2006.01.085.

    Article  CAS  PubMed  Google Scholar 

  52. Adelberg DA, Del Priore LV, Kaplan HJ. Surgery for subfoveal membranes in myopia, angioid streaks, and other disorders. Retina. 1995;15(3):198–205.

    Article  CAS  PubMed  Google Scholar 

  53. Thomas MA, Dickinson JD, Melberg NS, Ibanez HE, Dhaliwal RS. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology. 1994;101(8):1384–96.

    Article  CAS  PubMed  Google Scholar 

  54. Uemura A, Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol. 2000;118(3):344–50.

    Article  CAS  PubMed  Google Scholar 

  55. Hamelin N, Glacet-Bernard A, Brindeau C, Mimoun G, Coscas G, Soubrane G. Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am J Ophthalmol. 2002;133(4):530–6.

    Article  PubMed  Google Scholar 

  56. Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol. 1996;80(3):241–5.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81(2):154–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Bennett MD, Yee W. Pegaptanib for myopic choroidal neovascularization in a young patient. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2007;245(6):903–5. doi:10.1007/s00417-006-0472-6.

  59. Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina. 2008;28(9):1308–13. doi:10.1097/IAE.0b013e31818358b2.

    Article  PubMed  Google Scholar 

  60. Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR Study. Ophthalmology. 2015;122(6):1220–7. doi:10.1016/j.ophtha.2015.01.025.

    Article  PubMed  Google Scholar 

  61. Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121(3):682–92 e2. doi:10.1016/j.ophtha.2013.10.023.

  62. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009;147(1):94–100 e1. doi:10.1016/j.ajo.2008.07.017.

  63. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol. 2009;93(2):150–4. doi:10.1136/bjo.2008.145797.

    Article  PubMed  Google Scholar 

  64. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol. 2009;93(4):448–51. doi:10.1136/bjo.2008.145391.

    Article  CAS  PubMed  Google Scholar 

  65. Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina. 2009;29(6):750–6. doi:10.1097/IAE.0b013e31819ed6bd.

    Article  PubMed  Google Scholar 

  66. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab–a randomized controlled trial. Am J Ophthalmol. 2010;149(3):458–64 e1. doi:10.1016/j.ajo.2009.10.010.

  67. Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina. 2012;32(8):1539–46. doi:10.1097/IAE.0b013e31826956b7.

    Article  CAS  PubMed  Google Scholar 

  68. Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120(9):1944–5 e1. doi:10.1016/j.ophtha.2013.06.010.

  69. Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina. 2013;33(7):1375–92. doi:10.1097/IAE.0b013e31827d260a.

    Article  CAS  PubMed  Google Scholar 

  70. Gharbiya M, Allievi F, Conflitti S, Esposito M, Scavella V, Moramarco A, et al. Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study. La Clinica terapeutica. 2010;161(3):e87–93.

    CAS  PubMed  Google Scholar 

  71. Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Retina. 2011;31(9):1841–7. doi:10.1097/IAE.0b013e31821800a4.

    Article  CAS  PubMed  Google Scholar 

  72. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Ares S, Lopez-Lopez F, Rodriguez M, et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye. 2009;23(2):334–8. doi:10.1038/sj.eye.6703052.

    Article  CAS  PubMed  Google Scholar 

  73. Lai TY, Luk FO, Lee GK, Lam DS. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye. 2012;26(7):1004–11. doi:10.1038/eye.2012.97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Franqueira N, Cachulo ML, Pires I, Fonseca P, Marques I, Figueira J, et al. Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab. Ophthalmologica J Int d’ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkunde. 2012;227(1):39–44. doi:10.1159/000333213.

    Article  CAS  Google Scholar 

  75. Oishi A, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Nakata I, et al. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2013;251(1):1–7. doi:10.1007/s00417-012-2022-8.

  76. Yang HS, Kim JG, Kim JT, Joe SG. Prognostic factors of eyes with naive subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Am J Ophthalmol. 2013;156(6):1201–10 e2. doi:10.1016/j.ajo.2013.08.002.

  77. Ruiz-Moreno JM, Montero JA, Amat-Peral P. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2011;249(4):595–9. doi:10.1007/s00417-010-1599-z.

  78. Wakabayashi T, Ikuno Y, Gomi F. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Retina. 2011;31(5):880–6. doi:10.1097/IAE.0b013e3181f2a293.

    Article  CAS  PubMed  Google Scholar 

  79. Niwa Y, Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, et al. Comparison between one injection and three monthly injections of intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Res. 2012;47(3):135–40. doi:10.1159/000330499.

    Article  CAS  PubMed  Google Scholar 

  80. Kung YH, Wu TT, Huang YH. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Acta Ophthalmol. 2014;92(8):e615–20. doi:10.1111/aos.12457.

    Article  CAS  PubMed  Google Scholar 

  81. Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology. 2012;119(10):2082–6. doi:10.1016/j.ophtha.2012.07.041.

    Article  PubMed  Google Scholar 

  82. Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina. 2010;30(3):418–24. doi:10.1097/IAE.0b013e3181bd2fe4.

    Article  PubMed  Google Scholar 

  83. Chen L, Miller JW, Vavvas D, Kim IK. Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration. Retina. 2011;31(10):2078–83. doi:10.1097/IAE.0b013e3182109074.

    Article  CAS  PubMed  Google Scholar 

  84. Peiretti E, Vinci M, Fossarello M. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Can J Ophthalmol J Canadien d’ophtalmologie. 2012;47(1):28–33. doi:10.1016/j.jcjo.2011.12.009.

    Article  Google Scholar 

  85. Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Br J Ophthalmol. 2013;97(11):1447–50. doi:10.1136/bjophthalmol-2012-302973.

    Article  PubMed  Google Scholar 

  86. Ruiz-Moreno JM, Montero JA, Araiz J, Arias L, Garcia-Layana A, Carneiro A, et al. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia: six years outcome. Retina. 2015. doi:10.1097/iae.0000000000000632.

    Google Scholar 

  87. Sarao V, Veritti D, Macor S, Lanzetta P. Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2016;254(3):445–54. doi:10.1007/s00417-015-3076-1.

  88. Calvo-Gonzalez C, Reche-Frutos J, Donate J, Fernandez-Perez C, Garcia-Feijoo J. Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. Am J Ophthalmology. 2011;151(3):529–34. doi:10.1016/j.ajo.2010.09.021.

    Article  CAS  Google Scholar 

  89. Ahn SJ, Park KH, Woo SJ. Subfoveal choroidal thickness changes following anti-vascular endothelial growth factor therapy in myopic choroidal neovascularization. Invest Ophthalmol Vis Sci. 2015;56(10):5794–800. doi:10.1167/iovs.14-16006.

    Article  CAS  PubMed  Google Scholar 

  90. Uemoto R, Nakasato-Sonn H, Kawagoe T, Akira M, Okada E, Mizuki N. Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2012;250(7):989–97. doi:10.1007/s00417-011-1921-4.

  91. Ohno-Matsui K, Jonas JB, Spaide RF. Macular Bruch’s membrane holes in highly myopic patchy chorioretinal atrophy. Am J Ophthalmol. 2016. doi:10.1016/j.ajo.2016.03.019.

    Google Scholar 

  92. Saviano S, Piermarocchi R, Leon PE, Mangogna A, Zanei A, Cavarzeran Sc F, et al. Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: a one-year follow-up controlled study. Int J Ophthalmol. 2014;7(2):335–9. doi:10.3980/j.issn.2222-3959.2014.02.26.

    PubMed  PubMed Central  Google Scholar 

  93. Voykov B, Gelisken F, Inhoffen W, Voelker M, Bartz-Schmidt KU, Ziemssen F. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years? Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2010;248(4):543–50. doi:10.1007/s00417-009-1285-1.

  94. Nakanishi H, Tsujikawa A, Yodoi Y, Ojima Y, Otani A, Tamura H, et al. Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye. 2011;25(3):375–81. doi:10.1038/eye.2010.226.

  95. Ruiz-Moreno JM, Lopez-Galvez MI, Donate J, Gomez-Ulla F, Garcia-Arumi J, Garcia-Layana A, et al. Myopic choroidal neovascularization. Ophthalmology. 2011;118(12):2521–3. doi:10.1016/j.ophtha.2011.07.029.

    Article  PubMed  Google Scholar 

  96. Gharbiya M, Cruciani F, Parisi F, Cuozzo G, Altimari S, Abdolrahimzadeh S. Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol. 2012;96(8):1068–72. doi:10.1136/bjophthalmol-2012-301639.

    Article  PubMed  Google Scholar 

  97. Milani P, Massacesi A, Ciaccia S, Setaccioli M, Moschini S, Bergamini F. Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naive myopic choroidal neovascularization. Clin Ophthalmol. 2012;6:1885–94. doi:10.2147/OPTH.S34649.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Farinha CL, Baltar AS, Nunes SG, Franqueira NF, Figueira JP, Pires IA, et al. Choroidal thickness after treatment for myopic choroidal neovascularization. Eur J Ophthalmol. 2013;23(6):887–98. doi:10.5301/ejo.5000323.

    PubMed  Google Scholar 

  99. Wang J, Kang Z. Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2012;250(12):1717–23. doi:10.1007/s00417-012-2159-5.

  100. Ahn SJ, Woo SJ, Kim KE, Park KH. Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization. Invest Ophthalmol Vis Sci. 2013;54(3):2115–22. doi:10.1167/iovs.12-11542.

    Article  PubMed  Google Scholar 

  101. Meyer CH, Michels S, Rodrigues EB, Hager A, Mennel S, Schmidt JC, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol. 2011;89(1):70–5. doi:10.1111/j.1755-3768.2010.02064.x.

    Article  CAS  PubMed  Google Scholar 

  102. Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol. 2010;88(4):e136. doi:10.1111/j.1755-3768.2009.01572.x.

    Article  PubMed  Google Scholar 

  103. Rosen E, Rubowitz A, Ferencz JR. Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye. 2009;23(6):1479. doi:10.1038/eye.2008.218.

    Article  CAS  PubMed  Google Scholar 

  104. Tokoro T. On the definition of pathologic myopia in group studies. Acta Ophthalmol Suppl. 1988;185:107–8.

    CAS  PubMed  Google Scholar 

  105. Amoaku WM, Gale RP, Lotery AJ, Menon G, Sivaprasad S, Petrillo J, et al. Treatment satisfaction and well-being in patients with myopic choroidal neovascularization treated with ranibizumab in the REPAIR Study. PLoS One. 2015;10(6):e0128403. doi:10.1371/journal.pone.0128403.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Parodi MB, Iacono P, Papayannis A, Kontadakis S, Cascavilla ML, Zucchiatti I, et al. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia. Retina. 2013;33(3):593–7. doi:10.1097/IAE.0b013e31826b6731.

    Article  CAS  PubMed  Google Scholar 

  107. Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T, et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol. 2010;149(1):140–6. doi:10.1016/j.ajo.2009.08.008.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore, 168751, Singapore

    Kelvin Yi Chong Teo, Wei Yan Ng, Shu Yen Lee & Chui Ming Gemmy Cheung

  2. Duke-NUS Graduate Medical School, Singapore, Singapore

    Shu Yen Lee & Chui Ming Gemmy Cheung

  3. Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    Shu Yen Lee & Chui Ming Gemmy Cheung

Authors
  1. Kelvin Yi Chong Teo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Yan Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shu Yen Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chui Ming Gemmy Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chui Ming Gemmy Cheung.

Ethics declarations

Conflict of interest

GCM Cheung has previously received grants and honoraria from and is an invited speaker for Novartis and Bayer. KYC Teo, WY Ng, and SY Lee declare they have no conflicts of interest.

Funding

No funding was received for the preparation of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teo, K.Y.C., Ng, W.Y., Lee, S.Y. et al. Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy. Drugs 76, 1119–1133 (2016). https://doi.org/10.1007/s40265-016-0605-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-016-0605-0

Keywords

Search

Navigation